Eli Lilly's 61% market-implied probability of beating Q3 2026 non-GAAP EPS consensus reflects its four-quarter streak of outperformance, including a 39% EPS surprise in Q2, offset by analyst expectations for a year-over-year earnings decline amid elevated prior-period results. Strong volume growth in Mounjaro and Zepbound, particularly international sales and Medicare-supported demand, underpins revenue forecasts around $22 billion, while recent analyst actions such as Goldman Sachs' raised price target highlight potential for an upward guidance revision. Manufacturing expansions and pipeline updates provide additional support, though the high bar from prior beats introduces uncertainty ahead of the October 29 release. Trader consensus, backed by real capital, prices in these dynamics as the primary near-term catalyst.